REGULATORY

Chuikyo to Discuss Potential Pricing Steps to Deal with Higher Costs of Japan-Made APIs

March 13, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council (Chuikyo) is expected to hold discussions towards the end of the decade to consider ways to deal with the increased production costs that would result from using domestically manufactured APIs for four β-lactam antibiotics.…

To read the full story

How Will Japan Deal with Expected Cost Spike with Japan-Made Antibiotic APIs?
April 1, 2025

REGULATORY

LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
LDP’s Patch League Urges Finance Minister to Continue Coverage, Support Prices
December 16, 2025
Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025
LDP Leans Towards “Special Charges” for OTC-Like Drugs, Not Coverage Removal
December 15, 2025
Ishin Urges “Special Charge” Scheme for OTC-Like Drugs, Eyes FY2026 Launch
December 15, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…